Drug Profile

Thiotepa - Sumitomo Pharma

Alternative Names: DSP 1958; RETHIO; RITHIO^®

Latest Information Update: 05 Apr 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sumitomo Dainippon Pharma
Developer Sumitomo Pharma
Class Antineoplastics; Aziridines; Myeloablative agonists; Organothiophosphorus compounds
Mechanism of Action Alkylating agents; DNA synthesis inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Lymphoma; Solid tumours
No development reported Haematological disorders

Most Recent Events

01 Apr 2022 Sumitomo Dainippon Pharma is now called Sumitomo Pharma
26 Mar 2020 Launched for Lymphoma in Japan (IV)
25 Mar 2020 Registered for Lymphoma in Japan (IV)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com